Summary

Kite Pharma, Inc. is an American biotechnology company specializing in cancer immunotherapy with a primary focus on genetically engineered autologous CAR T cell therapy. Founded in 2009 and headquartered in Santa Monica, California, Kite was acquired by Gilead Sciences in 2017 for $11.9 billion. The company develops cell-based therapies that reengineer a patient's own immune cells to attack and fight cancer cells, representing a personalized approach to cancer treatment. Kite's lead product, Yescarta (axicabtagene ciloleucel), was the first CAR T therapy approved by the FDA for treating adult patients with relapsed or refractory large B-cell lymphoma. With approximately 2,000 employees and manufacturing facilities in California, Maryland, and the Netherlands, Kite operates as an independent company within Gilead Sciences while maintaining its singular focus on advancing cell therapy to treat and potentially cure cancer. The company's innovative approach represents a paradigm shift in cancer treatment, moving away from traditional pharmaceutical manufacturing to individualized cell therapies created one patient at a time.

Job description

Key Responsibilities

Execute manufacturing processes on the floor under supervision, following batch records, SOPs, and cGMP regulations to ensure safe and compliant operations.
Ensure right-the-first-time performance of all process steps specific to the phase or stage of operation and help drive the safety-first culture at Kite Oceanside.
Work as part of a team to execute GMP runs in close collaboration with MSAT, Facilities and Engineering (F&E), and Quality departments.
Perform weighing of raw materials and electronic inventory transactions utilizing MES and EBS.
Perform chromatography and UFDF purification unit operations for the manufacturing of viral vector products in a cGMP environment using proper aseptic technique, cleanroom behavior, GDP, and sound scientific methods.
Prepare and use single use systems to support buffer preparation and filter integrity testing.
Assist with manual and/or automated fill of harvested viral vector material.
Escalate processing and equipment issues as needed.
Assist with revisions of SOPs, Manufacturing Production Records (MPRs), and other controlled documents.
Assist in the review of in-process cGMP documentation for completeness, accuracy, and compliance.
Work effectively in an inclusive, cross-functional, team-based environment.
Work off shift hours, weekends, and overtime as needed.

Basic Qualifications

High School diploma with at least 3 years of relevant experience.
Associates degree with at least 2 years of relevant experience.
Bachelors degree with relevant experience.
Prior experience in a cGMP-regulated industry is required.

Requirements

High School diploma with at least 3 years of relevant experience, or Associates degree with at least 2 years of relevant experience, or Bachelors degree with relevant experience
Prior experience in a cGMP-regulated industry is required
Ability to work off shift hours, weekends, and overtime
Ability to work effectively in an inclusive, cross-functional, team-based environment

Benefits

Medical, Dental & Vision
Life Insurance
Paid Time Off
Discretionary Annual Bonus
Discretionary Stock-Based Long-Term Incentives

Company overview

Kite Pharma, Inc. is an American biotechnology company specializing in cancer immunotherapy with a primary focus on genetically engineered autologous CAR T cell therapy. Founded in 2009 and headquartered in Santa Monica, California, Kite was acquired by Gilead Sciences in 2017 for $11.9 billion. The company develops cell-based therapies that reengineer a patient's own immune cells to attack and fight cancer cells, representing a personalized approach to cancer treatment. Kite's lead product, Yescarta (axicabtagene ciloleucel), was the first CAR T therapy approved by the FDA for treating adult patients with relapsed or refractory large B-cell lymphoma. With approximately 2,000 employees and manufacturing facilities in California, Maryland, and the Netherlands, Kite operates as an independent company within Gilead Sciences while maintaining its singular focus on advancing cell therapy to treat and potentially cure cancer. The company's innovative approach represents a paradigm shift in cancer treatment, moving away from traditional pharmaceutical manufacturing to individualized cell therapies created one patient at a time.